Impetus Wellness Group

The firm targets early-stage biotechnology and digital health companies focused on extending healthspan, with confirmed interests in senolytic therapeutics, neuroplasticity, precision nutrition, and metabolic health. It provides direct equity and reserves capacity to follow on through clinical and regulatory milestones, operating less like a fund and more like a permanent-capital partner. The portfolio is concentrated, and the group has shown no appetite for therapeutics targeting late-stage disease management.

The office cultivates relationships directly with academic research institutions, biotechnology incubators, and founder-led biotech startups, often entering before a formal Series A syndicate is assembled. It co-invests alongside specialist life-science venture funds, leveraging its reputation as a patient, non-operator LP that will not force an exit timeline. There is no indication the group participates in the auction processes run by bulge-bracket investment banks.

The principals have not been publicly identified. The office operates with no public-facing executive roster, reflecting a deliberate governance choice to separate the investment entity from personal publicity. Public record confirms US jurisdiction, but no named investment committee members, trustees, or family members have been documented in regulatory filings or press coverage.

No. All available evidence indicates the group is a single-family office deploying proprietary capital. It has not registered as an investment adviser, has no known multi-family or third-party LP platform, and does not solicit external capital, consistent with the single-family office exemption under the Investment Advisers Act.

The firm concentrates on pre-clinical to Series A biotechnology companies, re-entering at Series B or beyond when a portfolio company reaches a specific biological efficacy signal. It has not been observed participating in late-stage mezzanine rounds or pre-IPO crossovers, consistent with a strategy that values cheap, illiquid, binary-risk entry points over liquidity-optionality trades.